Request Line: (870) 277-1080 [email protected]
Text Your Gift to KLEK1 to 44-321 LEARN MORE

Your Community Radio Station is possible thanks to this supporter!  Become an underwriter.

Cotton, Gallagher Introduce Bill to End U.S. Dependence on Chinese-Manufactured Pharmaceuticals

Written by Press Release

March 18, 2020

Washington, D.C. – Senator Tom Cotton (R-Arkansas) and Congressman Mike Gallagher (R-Wisconsin) will tomorrow introduce the Protecting our Pharmaceutical Supply Chain from China Act, which would end U.S. dependence on China for pharmaceutical manufacturing. The bill’s key restrictions would go into effect in 2022 and have no impact on the current coronavirus pandemic. No FDA resources will be diverted to begin implementation. Specifically, the bill will:

  1. Track active pharmaceutical ingredients through an FDA registry.
  2. Prohibit pharmaceutical purchases from China or products with active pharmaceutical ingredients created in China*.
  3. Create transparency in the supply chain by instituting a country of origin label of all imported drugs.
  4. Provide economic incentives for manufacturing drugs and medical equipment in the United States.

“The Chinese Communist Party has threatened to cut off America’s access to vital drugs in the midst of a pandemic caused by its own failures. It’s time to pull America’s supply chains for life-saving medicine out of China and make the CCP pay for contributing to this global emergency,” said Cotton.

“The Chinese Communist Party’s outrageous threats to withhold lifesaving drugs from the U.S. endangers public health and should open our eyes to our dangerous over-reliance on China in our medical supply chain,” said Gallagher. “This is a national security imperative that to many Americans, is a matter of life and death. It’s past time for us to develop an aggressive plan to move critical pharmaceutical supply chains away from China.”

Click here for a one-pager on the bill.

* This requirement will be phased in over two years. The FDA may issue waivers if the active pharmaceutical ingredients are only available in China, however, no waivers may be issued after 2024.

Original article source: http://www.cotton.senate.gov?p=press_release&id=1342 | Article may or may not reflect the views of KLEK 102.5 FM or The Voice of Arkansas Minority Advocacy Council

0 0 vote
Article Rating

Related Articles

Cotton Introduces Bill to End China’s Permanent Most-Favored-Nation Status

FOR IMMEDIATE RELEASEContact: Caroline Tabler or James Arnold (202) 734-0430 September 17, 2020   Cotton Introduces Bill to End China’s Permanent Most-Favored-Nation Status   Washington, D.C. — Senator Tom Cotton (R-Arkansas) today introduced Read more

Cotton on Fox News ‘Netflix’s ‘Cuties’ is child pornography hiding in plain sight ? it is Hollywood exploitation’

Netflix's 'Cuties' is child pornography hiding in plain sight - it is Hollywood exploitationBy: Senator Tom CottonSeptember 15, 2020People can disagree about all manner of issues - and in America, Read more

Cotton, Gallagher Raise Chinese Lobbying Concerns to DOJ

     FOR IMMEDIATE RELEASE Contact: Caroline Tabler or James Arnold (202) 734-0430 September 15, 2020   Cotton, Gallagher Raise Chinese Lobbying Concerns to DOJ Washington, D.C. — Senator Tom Cotton (R-Arkansas) and Read more

Cotton Statement on Agreement Between Israel and Bahrain

Washington, D.C. - Senator Tom Cotton (R-Arkansas) today released the following statement on the normalization of diplomatic relations between Israel and Bahrain:"Today's agreement between Israel and Bahrain is yet another Read more

Comments

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Your Community Radio Station is possible thanks to this supporter!  Become an underwriter.

Pin It on Pinterest